← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIMYCOBACTERIALS › DRUGS FOR TREATMENT OF TUBERCULOSIS › Other drugs for treatment of tuberculosis
terizidone
J04AK03
Adult Dosing
- Tuberculosis (pulmonary or extrapulmonary, drug-resistant): 10 to 15 mg/kg/day orally in divided doses (usually 500 mg to 750 mg daily, occasionally up to 1 g/day)
Pediatric Dosing
- Safety and efficacy in pediatric patients not fully established; use restricted to resistant tuberculosis under expert guidance: 10 to 20 mg/kg/day orally in divided doses
Indications
- Second-line treatment of tuberculosis caused by Mycobacterium tuberculosis strains resistant to primary agents (e.g., isoniazid, rifampin), used in combination regimens
Mechanism of Action
- Analogue of D-alanine; competitively inhibits two bacterial enzymes (alanine racemase and D-alanyl-D-alanine ligase), preventing incorporation of D-alanine into the peptidoglycan cell wall and inhibiting cell wall synthesis
Contraindications
- Hypersensitivity to terizidone or cycloserine
- Epilepsy or history of generalized seizures
- Severe depression, severe anxiety, or psychosis
- Severe renal impairment (creatinine clearance < 50 mL/min)
Adverse Reactions
- Central nervous system toxicity (somnolence, headache, dizziness, vertigo, tremors, confusion, psychosis, convulsions)
- Peripheral neuropathy
- Visual disturbances
- Allergic skin reactions
- Elevated transaminases
Drug Interactions
- Alcohol: increases risk of seizures and neurotoxicity
- Ethionamide: synergistic neurotoxicity and central nervous system side effects
- Isoniazid: increased incidence of central nervous system toxicity (dizziness, drowsiness)
- Phenytoin: increased metabolism or risk of toxicity (anticonvulsant efficacy may be altered)
Curated Content: Needs Vetting Before Put to Clinical Use